Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
Details : The insulin delivery technology company with the first FDA-cleared patch pump, designed specifically to target all adult "almost-pumpers," offers a user-friendly and affordable solution for obesity.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Not Applicable
November 07, 2024
Lead Product(s) : Insulin
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GUB014295
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Modular Medical Announces Proof-of-Concept for Personalized Metabolic Therapy
Details : GUB014295 is a long acting GLP-1 analog injectables, it is being developed for the treatment of patients with overweight.
Product Name : GUB014295
Product Type : Peptide
Upfront Cash : Not Applicable
July 15, 2024
Lead Product(s) : GUB014295
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?